Schreiner MediPharm introduces new tamper-evident flexi-cap prime for vials

  • Schreiner MediPharm

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, has developed a new label-cap combination that protects the integrity of original medicine containers, helping to prevent illegal reuse through clear, irreversible first-opening indication.

At CPhI Worldwide in Frankfurt, November 5-7, the company will present Flexi-Cap Prime, the latest addition to its Flexi-Cap portfolio of security solutions offering even higher degrees of safety.

Empty medicine containers with original labels can be filled with ineffective or harmful substitutes and reintroduced into the market by counterfeiters, posing risks to patients and challenges to pharmaceutical manufacturers.

Complex construction, easily integrated into production processes

To help counteract this, a special feature of Flexi-Cap Prime is its complex construction, including a tear strip running through both the film cap and the label. When the tear strip is opened at the starter tab, it simultaneously destroys the cap and the label so that undetected reuse of the container is no longer possible.

Like all products in the Flexi-Cap family, Flexi-Cap Prime can easily be integrated into a pharmaceutical manufacturer’s production processes. It is also applied without heat, and can be flexibly adapted to diverse container types, shapes and sizes while the label’s design and the pharma manufacturer’s brand appearance remain unchanged. The integration of additional features, such as counterfeiting protection elements, offers further opportunities for securing the supply chain.

For healthcare staff, the newly developed Flexi-Cap Prime is ideal, too: It ensures the integrity of the vial until its final application. Flexi-Cap Prime is easy to use and enables fast and efficient first-opening verification. Thus, patients can be protected against the administration of ineffective and potentially harmful medications.

Other highlights at Schreiner MediPharm’s booth (Hall 11.1, Booth C45) include Cap-Lock, the novel combination of a tamper-proof cap adapter plus label for syringes, and smart labels with integrated NFC/RIFD functionality for a wide range of interactive applications.

Caption: Due to its combined tear strip for the label and cap, the new Flexi-Cap Prime offers even higher safety.

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Jo Webb
  • Product Info
  • English
  • Created 10 Oct 2019
  • Modified 11 Oct 2019
  • Hits 179